Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

Hyderabad: Granules India, a vertically integrated Indian pharmaceutical company, has announced the resignation of Riaz Ahmed ...

Granules India reported a drop in third-quarter profit on Friday, hurt by pricing pressure in its key European market.

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, has announced that its wholly-owned ...

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

Granules India's revenue decreased by 1.6% year-on-year for the three months ended Dec. 31, 2024, reaching Rs 1,138 crore.

Granules India receives USFDA approval for its generic Lisdexamfetamine Dimesylate capsules, indicated for the treatment of ...